ImmuPharma (LSE:IMM) has appointed Kymos Group as its bioanalytical contract research partner for the Kapiglucagon development programme following a competitive tender process. The appointment represents another step in advancing the drug candidate through its non-clinical and early clinical development stages.
The collaboration adds to ImmuPharma’s existing development partnerships, which include Thermo Fisher for chemistry, manufacturing and controls activities and Bachem for active pharmaceutical ingredient manufacturing. Together, these relationships form part of a streamlined development strategy for Kapiglucagon, with the company also assessing the potential use of the 505(b)(2) regulatory pathway in the US to shorten the route towards commercialisation.
Kapiglucagon has been developed to address one of the limitations of native glucagon: its instability in aqueous formulations. ImmuPharma’s candidate is a water-soluble glucagon prodrug designed to be compatible with pumps and suitable for continuous delivery as part of dual-hormone artificial pancreas systems.
The technology could potentially support improved glucose management for people with Type 1 diabetes by allowing insulin and glucagon to be administered through advanced automated delivery systems. If successfully developed, this approach could help improve glucose control while reducing the day-to-day burden of managing the condition.
Backed by recent funding and an expanding package of preclinical and CMC data, ImmuPharma intends to pursue regulatory interactions and targeted clinical studies to progress Kapiglucagon. The programme represents a potentially important addition to the company’s pipeline as it seeks exposure to the emerging market for next-generation diabetes management technologies.
However, ImmuPharma’s financial position remains a key consideration, with the company generating no revenue and continuing to report losses and cash consumption, alongside a relatively fragile equity position. Low debt provides some balance sheet support, while technical indicators remain moderately negative due to a weaker longer-term share price trend and bearish MACD. Traditional valuation measures remain of limited relevance while the company remains loss-making.
More about ImmuPharma
ImmuPharma is a UK-listed specialty biopharmaceutical company focused on the discovery and development of peptide-based therapeutics. Its pipeline covers potential treatments for autoimmune diseases and anti-infective indications and includes its lead P140 programme alongside Kapiglucagon, a proprietary glucagon prodrug being developed for Type 1 diabetes and advanced artificial pancreas systems.
Leave a Reply